A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients through Month 36 posttransplant. Patients will continue their study medications that were previously assigned.
Inclusion Criteria:
Exclusion Criteria:
Chapel Hill, North Carolina 27514, United States
Chapel Hill, North Carolina 27599-7211, United States
Chapel Hill, North Carolina 27599-7211, United States
Chapel Hill, North Carolina 27599-7360, United States
Chapel Hill, North Carolina 27599, United States
Philadelphia, Pennsylvania 19102, United States
Charleston, South Carolina 29425, United States
Dallas, Texas 75246, United States
Adelaide, South Australia 5000, Australia
Porto Alegre, Rio Grande do Sul 90020-090, Brazil
Praha 4 Krc, 140 21, Czechia
Seoul, 120-752, South Korea